Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Study of Chemotherapy with Hycanthone for Advanced Colorectal Carcinoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Completed

no age specified

MAYO-774603

Objectives

I.  Determine the toxicity and efficacy of chemotherapy with hycanthone in 
colorectal carcinoma.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with histologically 
confirmed, measurable, residual, recurrent or metastatic colorectal 
adenocarcinoma not amenable to surgery or radiotherapy.  Patients must have 
adequate renal and hepatic function, an ECOG Performance Status of less than 
4, and must not have had prior surgery, radiation or chemotherapy within 4 
weeks.

Expected Enrollment

Protocol closed 07/78.  Protocol terminated 09/78.

Outline

Nonrandomized study.
Regimen:  Single-agent Chemotherapy.  Hycanthone mesylate, NSC-142982.

Trial Contact Information

Trial Lead Organizations

Mayo Clinic Cancer Center

Charles G. Moertel, MD, Protocol chair(Contact information may not be current)
Ph: 507-284-2511

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.